The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs 15,000 crore and scheme tenure up to FY 2027-28. The scheme provides financial incentives to 55 selected applicants for manufacturing identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for the treatment of rare diseases. Under the scheme, a total of 8 orphan drugs have been approved for manufacturing. The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:
|
Sr. No. |
Name of the product |
Usage |
|
1 |
Nitisinone |
Treatment of Hereditary Tyrosinemia Type 1 |
|
2 |
Nusinersen |
Treatment of Spinal Muscular Atrophy |
|
3 |
Rufinamide |
Treatment of Lennox-Gastaut syndrome. |
|
4 |
Sodium Phenyl Butyrate |
Treatment of Urea Cycle Disorders |
|
5 |
Tiopronin |
Prevention of Cystine Nephrolithiasis |
|
6 |
Trientine Hydrochloride |
Treatment of Wilson’s disease |
|
7 |
Eliglustat |
Treatment of Gaucher’s disease |
|
8 |
Cannabidiol |
Treatment of Dravet-Lennox Gastaut syndrome |
This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Lok Sabha.